Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
about
Cell delivery of therapeutic nanoparticlesDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyNanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.In vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsionsPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsEndosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Towards nanomedicines for neuroAIDS.Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.Cell-mediated drug delivery.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesAnti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophagesEfficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neuronsThe critical need for alternative antiretroviral formulations, and obstacles to their development.Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.Rodent models for HIV-associated neurocognitive disorders.Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized miceGold nanoparticles to improve HIV drug delivery.Investigational reverse transcriptase inhibitors for the treatment of HIV.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityOvercoming pharmacologic sanctuaries.Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyNovel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells.Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsNanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemNano-ART and NeuroAIDS.A recent trend of drug-nanoparticles in suspension for the application in drug delivery.Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissuesAntiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Interview: Nanomedicine and the fight against HIV/AIDS.Applications of nanoparticle systems in drug delivery technology.Creation of a long-acting nanoformulated dolutegravir.
P2860
Q28385606-3CC93EE3-C3B1-4E35-BB6B-A9B534D42F57Q28486428-D736F017-DC68-4241-AD66-61B481D742F2Q28551873-37F18A24-81C7-477F-9AA9-9E5231DCA4F3Q30387307-10E4BC38-CEBC-4C36-BF7A-4AFF34E2C198Q30469832-ABBF7A21-D747-4875-BA49-9E1B0B5980FAQ30603781-063D06AF-22D0-4A0E-99DE-CE80A9893FC7Q33614467-B30F8C51-4927-467D-B463-EA6E573E043CQ34059457-FDB50F67-B14F-4B91-8C4D-F47F6DA2D613Q34495140-A65F89FF-334D-4E3B-8A56-9ED1E054412DQ34639923-8F076BFA-3D5F-4E9E-B485-E10B03E0A5D7Q34709440-55EC16BC-E874-4C9D-9D80-66FE5B18A3CFQ34728884-08DC9EC6-70B1-4EFC-A892-AA185AC44973Q34745586-AD1672C3-0F9C-43DD-8999-E964F7E4113BQ34797004-110597B5-9BAB-47D1-B305-1BFFDA3BE8EEQ34869449-9A0313E1-9977-47CC-8CAD-7028DFA124C9Q35016131-803A4812-754B-4164-A4B1-8870D8720573Q35145361-4A64C634-89CA-4E70-8064-E436E1BE36BFQ35164438-DD470506-759C-47D3-BFA3-FBBA905D9ACDQ35194750-A2AF2A16-8936-4B9E-9886-FBACA6F44E1DQ35677168-4288B68A-AFB2-4295-88D0-91E7FB24A316Q35803957-2FF398D3-C1FB-4183-A50D-CEC697036649Q35822619-4A000067-20EB-46CD-8C9A-1FD3E3942955Q35847982-069BC3C0-92B3-48A5-A74B-F5129B1E92B2Q36306231-91B58254-6778-4BEC-AA43-9653C550230FQ36603756-9336C546-6912-47B7-B4BE-5424847169F9Q36875347-EA68AAE9-D1E1-4383-82B1-418BB8996F34Q36915933-830DD8D6-0169-4AA7-B225-DB30A497D2BBQ36969787-5557D3A9-4646-4AE7-B447-C8DB28E7CAA6Q37095750-81B9F054-8442-403D-ADDD-2BB3487A6E17Q37188867-7145C56E-2B0A-4FC4-A595-BC7D99EB65EFQ37698620-9BAE4725-769C-4DA7-8F63-5E6669B42605Q38823456-EFEC65FC-C3C5-4D31-BBD2-2964B32D3FC6Q38985268-D1F39F32-77F2-4FE0-8312-30DAEC87376CQ41905223-01F029BE-6E09-4218-914C-333E4917E2CFQ42844098-96315840-20A1-4B43-9DA3-3EBAFCF73D28Q46448056-0DF096F8-52AD-422B-800B-05998B27010CQ48375952-17820F6C-CDBD-43D2-A0B5-622F5B0F4CA8Q49197456-3D862F6C-7188-4570-9806-53099C26101FQ50051618-0BB7B9DB-4FEC-4798-8714-6AD708D925B2
P2860
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@ast
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@en
type
label
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@ast
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@en
prefLabel
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@ast
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@en
P2093
P2860
P1476
Nanoformulated antiretroviral ...... ns for neuroAIDS therapeutics.
@en
P2093
Alec Anderson
Ari S Nowacek
Barrett Rabinow
Howard E Gendelman
JoEllyn McMillan
Reagan Miller
P2860
P2888
P304
P356
10.1007/S11481-010-9198-7
P577
2010-03-17T00:00:00Z